Stockreport

Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q

Entero Therapeutics Inc.  (ENTO) 
PDF BOCA RATON, Fla., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceut [Read more]